Literature DB >> 30190894

The use of dendritic cell vaccinations in melanoma: where are we now?

Altuna Halilovic1,2,1,2, Kalijn F Bol1,3,1,3.   

Abstract

Entities:  

Keywords:  dendritic cell vaccine; immunotherapy; melanoma

Year:  2016        PMID： 30190894      PMCID： PMC6094693          DOI： 10.2217/mmt-2016-0027

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN： 2045-0885


× No keyword cloud information.
  22 in total

1.  Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.

Authors:  Beatriz M Carreno; Vincent Magrini; Michelle Becker-Hapak; Saghar Kaabinejadian; Jasreet Hundal; Allegra A Petti; Amy Ly; Wen-Rong Lie; William H Hildebrand; Elaine R Mardis; Gerald P Linette
Journal:  Science       Date:  2015-04-02       Impact factor: 47.728

2.  Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

Authors:  D Schadendorf; S Ugurel; B Schuler-Thurner; F O Nestle; A Enk; E-B Bröcker; S Grabbe; W Rittgen; L Edler; A Sucker; C Zimpfer-Rechner; T Berger; J Kamarashev; G Burg; H Jonuleit; A Tüttenberg; J C Becker; P Keikavoussi; E Kämpgen; G Schuler
Journal:  Ann Oncol       Date:  2006-01-17       Impact factor: 32.976

3.  Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.

Authors:  Sofie Wilgenhof; Jurgen Corthals; Carlo Heirman; Nicolas van Baren; Sophie Lucas; Pia Kvistborg; Kris Thielemans; Bart Neyns
Journal:  J Clin Oncol       Date:  2016-02-29       Impact factor: 44.544

Review 4.  Dendritic Cell-Based Immunotherapy: State of the Art and Beyond.

Authors:  Kalijn F Bol; Gerty Schreibelt; Winald R Gerritsen; I Jolanda M de Vries; Carl G Figdor
Journal:  Clin Cancer Res       Date:  2016-04-15       Impact factor: 12.531

Review 5.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

Review 6.  Clinical use of dendritic cells for cancer therapy.

Authors:  Sébastien Anguille; Evelien L Smits; Eva Lion; Viggo F van Tendeloo; Zwi N Berneman
Journal:  Lancet Oncol       Date:  2014-06       Impact factor: 41.316

7.  Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells.

Authors:  F J Hsu; C Benike; F Fagnoni; T M Liles; D Czerwinski; B Taidi; E G Engleman; R Levy
Journal:  Nat Med       Date:  1996-01       Impact factor: 53.440

8.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.

Authors:  Lena M Kranz; Mustafa Diken; Heinrich Haas; Sebastian Kreiter; Carmen Loquai; Kerstin C Reuter; Martin Meng; Daniel Fritz; Fulvia Vascotto; Hossam Hefesha; Christian Grunwitz; Mathias Vormehr; Yves Hüsemann; Abderraouf Selmi; Andreas N Kuhn; Janina Buck; Evelyna Derhovanessian; Richard Rae; Sebastian Attig; Jan Diekmann; Robert A Jabulowsky; Sandra Heesch; Jessica Hassel; Peter Langguth; Stephan Grabbe; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2016-06-01       Impact factor: 49.962

Review 9.  Dendritic cell vaccines in melanoma: from promise to proof?

Authors:  W J Lesterhuis; E H J G Aarntzen; I J M De Vries; D H Schuurhuis; C G Figdor; G J Adema; C J A Punt
Journal:  Crit Rev Oncol Hematol       Date:  2008-02-08       Impact factor: 6.312

10.  Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients.

Authors:  Steve Boudewijns; Harm Westdorp; Rutger H T Koornstra; Erik H J G Aarntzen; Gerty Schreibelt; Jeroen H A Creemers; Cornelis J A Punt; Carl G Figdor; I Jolanda M de Vries; Winald R Gerritsen; Kalijn F Bol
Journal:  J Immunother       Date:  2016 Jul-Aug       Impact factor: 4.456
View more
  1 in total

1.  Naturally produced type I IFNs enhance human myeloid dendritic cell maturation and IL-12p70 production and mediate elevated effector functions in innate and adaptive immune cells.

Authors:  Annette E Sköld; Till S M Mathan; Jasper J P van Beek; Georgina Flórez-Grau; Michelle D van den Beukel; Simone P Sittig; Florian Wimmers; Ghaith Bakdash; Gerty Schreibelt; I Jolanda M de Vries
Journal:  Cancer Immunol Immunother       Date:  2018-07-13       Impact factor: 6.968
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.